biostudies-literatureUnknownRamlakhan KPEdwards LifesciencesBoston Scientific CorporationFondazione Internazionale MenariniStichting ZabawasBristol-Myers SquibbAmgenDe Hoop FoundationVifor PharmaPfizerNovartis PharmaBayerGedeon RichterEli Lilly and CompanyResMed FoundationBoehringer IngelheimDaiichi Sankyo CompanyAstraZenecaServierSanofiAbbott Vascular Int.Merck Sharp and Dohme<h4>Objective</h4>Pregnancy in women with aortic coarctation (CoA) has an estimated moderately increased risk (mWHO II-III) of adverse cardiovascular, obstetric or fetal events, but prospective data to validate this risk classification are scarce. We examined pregnancy outcomes and identified associations with adverse outcomes.<h4>Methods</h4>Pregnancies in women with CoA were selected from the worldwide prospective Registry of Pregnancy and Cardiac Disease (ROPAC, n=303 out of 5739), part of the European Society of Cardiology EURObservational Research Programme. The frequency of and associations with major adverse cardiac events (MACE) and hypertensive disorders (pregnancy-induced hypertension, (pre-)eclampsia or haemolysis, elevated liver enzymes and low platelets syndrome) were analysedHeart (British Cardiac Society)heartjnl-2020-317513https://www.ebi.ac.uk/biostudies/studies/S-EPMC7873427biostudies-literaturePregnancy outcomes in women with aortic coarctation.PMC7873427Manga PTobler DJohnson MRRamlakhan KPNihoyannopoulos PSchwerzmann MHall RMaggioni APBaris LGreutmann MRoos-Hesselink JWROPAC investigators groupYetman ATBoersma EfalsePregnancy outcomes in women with aortic coarctation.<h4>Objective</h4>Pregnancy in women with aortic coarctation (CoA) has an estimated moderately increased risk (mWHO II-III) of adverse cardiovascular, obstetric or fetal events, but prospective data to validate this risk classification are scarce. We examined pregnancy outcomes and identified associations with adverse outcomes.<h4>Methods</h4>Pregnancies in women with CoA were selected from the worldwide prospective Registry of Pregnancy and Cardiac Disease (ROPAC, n=303 out of 5739), part of the European Society of Cardiology EURObservational Research Programme. The frequency of and associations with major adverse cardiac events (MACE) and hypertensive disorders (pregnancy-induced hypertension, (pre-)eclampsia or haemolysis, elevated liver enzymes and low platelets syndrome) were analysed2020-01-01T00:00:00Z2020 Oct2026-07-16T00:40:51.042Z2026-07-09T10:25:58.677ZS-EPMC78734273312230110.1136/heartjnl-2020-317513